喹硫平联合氟哌啶醇治疗精神分裂症急性期兴奋激越的效果研究

Effect of Quetiapine Combined Haloperidol on Excitatory Agitation in Acute Stage of Schizophrenia

目的:探讨喹硫平联合氟哌啶醇治疗精神分裂症急性期兴奋激越的应用方法及效果。方法:选择笔者所在医院2017年1月-2018年6月收治的精神分裂症急性期兴奋激越患者共40例。采用随机数字表法将其分为观察组与对照组,各20例。对照组患者给予氟哌啶醇进行治疗,观察组患者给予喹硫平联合氟哌啶醇进行治疗,比较两组临床治疗效果、治疗前后PANSS-EC减分值评分及静坐不能、肌强直、扭转性、震颤等不良反应发生情况。结果:治疗前及治疗8周后两组PANSS-EC减分值比较差异无统计学意义(P>0.05),治疗12周后观察组减分值高于对照组,差异有统计学意义(P<0.05)。观察组临床治疗总有效率为80.0%,高于对照组的50.0%,差异有统计学意义(P<0.05)。观察组不良反应发生率为25.0%,低于对照组的85.0%,差异有统计学意义(P<0.05)。结论:采用喹硫平联合氟哌啶醇治疗精神分裂症急性期兴奋激越患者,临床疗效良好,症状改善明显,不良反应较少,安全可靠,具有很高的临床应用价值,值得广泛推广和应用。

Objective: To investigate the application and effect of Quetiapine and Haloperidol in treatment of acute excitatory schizophrenia. Method: A total of 40 patients with acute excitatory schizophrenia who were admitted to our hospital from January 2017 to June 2018 were enrolled. The patients were divided into two groups: the observation group and the control group, 20 patients in each group. The patients in the control group were treated with Haloperidol. The patients in the observation group were treated with Quetiapine combined Haloperidol. The clinical treatment effect of the patients, the PANSS-EC subtraction scores before and after treatment, and the adverse reactions such as sitting discomfort, myotonia, torsion, and tremor were compared. Result: There was no significant difference in PANSS-EC subtraction score between the two groups before treatment and 8 weeks after treatment. After 12 weeks of treatment, the subtraction score of the observation group was higher than that of the control group, the difference was statistically significant (P<0.05). The total effective rate of clinical treatment in the observation group was 80.0%, which was significantly higher than that in the control group the difference was statistically significant (P<0.05). The incidence of adverse reactions in the observation group was 25.0%, which was lower than 85.0% in the control group, the difference was statistically significant (P<0.05). Conclusion: The use of Quetiapine combined with Haloperidol in the treatment of patients with acute excitatory schizophrenia has good clinical efficacy, the improvement of symptoms is obvious, the adverse reactions are few, safe and reliable, and has high clinical application value, which is worth popularizing and applying widely.